What Profinal Treats: Main Uses and Benefits

Profinal is relevant in contexts involving heightened systemic burden, applied across domains where short-term symptom management is appropriate. This medication is used in areas where short-term symptomatic assistance is appropriate.

This medicine is relevant for easing symptoms related to inflammatory or irritative states and is commonly used across conditions involving episodic or fluctuating manifestations. It is applied in clinical settings that involve acute or unstable symptom patterns, which may lead to temporary functional strain or discomfort. This includes symptomatic relief from headache, dental pain, muscle aches, backache, menstrual cramps, and fever.

“The use of Profinal may be part of symptomatic management when symptoms become more disruptive during flare-ups.”

It is applied in addressing symptom clusters that interfere with daily comfort, which may help patients cope more steadily with symptom fluctuations. This supports general well-being during symptomatic phases.

Quick Fact: Relief for Inflammation Profinal is commonly used to help with symptoms related to inflammatory or irritative states.

Official Eligibility and Non-Eligibility for Profinal (Ibuprofen)

Regulatory authorities define eligibility for Profinal based on age, physiological status, and underlying diseases, classifying use as allowed, restricted, or strictly prohibited (contraindicated).

Category	Official Regulatory Classification
Populations for whom use is allowed	Adults and Adolescents (generally ge 12 years). Children ge 6 months for liquid forms.
Populations for whom use is not recommended	Women attempting to conceive. Infants below the minimum established age/weight threshold.
Populations for whom use is contraindicated	Patients with severe heart, renal, or hepatic failure. Patients with active or recurrent peptic ulceration/hemorrhage. Patients with known NSAID hypersensitivity or aspirin-sensitive asthma. Patients undergoing Coronary Artery Bypass Graft (CABG) surgery.

Age-Related and Physiological Restrictions

• Infants: Use is often categorized as not established below specific age limits (e.g., six months).
• Older Adults (Geriatric): Use requires caution due to increased susceptibility to gastrointestinal and renal adverse effects.
• Pregnancy: Contraindicated during the third trimester (from 20 or 30 weeks onward) due to the risk of fetal cardiopulmonary toxicity. Use during the first and second trimesters is not recommended unless essential.

Condition-Specific Limitations

Populations with uncontrolled hypertension, mild-to-moderate heart failure, or a history of Gastrointestinal disease (such as Crohn's or Ulcerative Colitis) should only be treated with restricted or conditional use, often involving the avoidance of high doses (ge 2400 mg/day) as stated in regulatory warnings.

Interactions with other medicines and products

The regulatory profile for Profinal (Ibuprofen) identifies interactions categorized by pharmacodynamic and pharmacokinetic mechanisms. Co-administration is formally contraindicated with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 specific inhibitors, and with analgesic doses of Acetylsalicylic Acid (Aspirin) above 75 mg/day. This restriction is based on the risk of additive toxicity.

A specific timing separation is required when co-administering with low-dose antiplatelet Aspirin. Ibuprofen must be taken at least eight hours before or thirty minutes after the low-dose Aspirin to avoid interference with its antiplatelet effects.

Documented pharmacodynamic interactions increase the risk of bleeding when Profinal is combined with agents such as Anticoagulants (Warfarin), Antiplatelet agents, and SSRIs. Other PD interactions reduce the therapeutic efficacy of Diuretics and ACE Inhibitors/ARBs, while increasing the risk of acute renal impairment.

The pharmacokinetic profile shows that Ibuprofen can increase the systemic exposure of co-administered drugs like Lithium and Methotrexate by officially reducing their renal clearance. Conversely, CYP2C9 inhibitors (e.g., Fluconazole) may increase Ibuprofen plasma concentration. The profile notes that elderly patients face increased susceptibility to these adverse pharmacodynamic effects, and caution is advised regarding the use of Alcohol due to the officially documented increased risk of gastrointestinal bleeding.

How Profinal Works: Mechanism of Action

Profinal's primary mechanistic domain is the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzyme family, specifically targeting both COX-1 and COX-2. This molecular action occurs at the active site of the enzymes, preventing them from carrying out their essential catalytic function of converting arachidonic acid into prostanoids.

By blocking the COX enzymes, Profinal suppresses the synthesis of key inflammatory signals, particularly prostaglandin PGE2. This interruption acts within domains involving humoral mediator responses, limiting the impact of elevated mediator activity that sensitizes peripheral pain neurons and centrally alters the hypothalamic temperature set-point.

The resulting physiological effects include both peripheral and central action. It contributes to stabilizing peripheral nerve-ending activity and influences the hypothalamic thermoregulatory system, leading to the predictable physiological adjustments of reduced localized vascular changes, nociceptive signaling, and elevated body temperature.

How to Use Profinal: Official Administration Guidelines

The following instructions detail the administration of Profinal.

---

Administration Details

Feature	Official Instruction
Route of Administration	Oral.
Timing in Relation to Meals	Preferably taken after food to minimize potential side effects.
Duration of Use	For short-term use only. For example, the Paracetamol/Ibuprofen combination product should not be used for more than 3 days without consulting a physician.

---

Dosing and Preparation

Standard Adult Dosing (Ibuprofen Component):

The maximum single dose should generally not exceed 800 mg, and the total daily dose should typically not exceed 2400 mg of Ibuprofen, taken in divided doses. When using the Paracetamol/Ibuprofen combination powder, the dose is generally one sachet per administration.

Frequency:

Doses must be spaced apart by a minimum interval. For the combination powder, the interval between doses must be at least six hours, and the medicine may be taken up to three times a day, as required.

Preparation (Powder):

If using the powder for oral solution, the contents of the sachet must be fully dissolved in a glass of hot water prior to consumption. Tablets should be swallowed whole with water.

Special Patient Groups:

Dosing for children is typically calculated based on age or body weight (e.g., in mg per kg of body weight), and the lowest effective dose for the shortest duration necessary should be used across all populations, including the elderly.

Research evidence / Overview of studies for Profinal

The evidence base for Profinal (Ibuprofen) is substantial, primarily drawing from regulatory reviews of clinical trials and large-scale scientific syntheses. Research has explored how symptoms change over time in different groups of people, contributing to the broader evidence landscape that informs regulatory reviews.

---

Evidence for use in Acute Pain Relief

Research has been conducted exploring short-term symptom changes related to acute physical discomfort, such as pain following minor surgery, dental procedures, or musculoskeletal injuries. The evidence base includes numerous short-term Randomized Controlled Trials (RCTs). These studies were designed to examine outcomes related to symptom intensity or variability, typically measuring patient-reported discomfort using standardized scales. Research examined the duration of measured symptom change and the requirement for additional pain management methods.

---

Evidence for use in Fever Reduction (Antipyresis)

Studies explored the medicine’s use for outcomes related to systemic or functional imbalance, specifically fever. The core evidence consists of numerous RCTs and comprehensive Meta-Analyses which research describes. These studies monitored physiological strain or stress by examining body temperature as the primary outcome. Findings describe patterns observed in the studies, including the time required for the greatest measured temperature change and the overall evolution of fever during the observation periods.

---

Evidence for Chronic Inflammatory Symptom Management

The medicine was evaluated in conditions characterized by fluctuating or episodic manifestations, such as certain forms of arthritis or primary dysmenorrhea. Research examined outcomes related to physical discomfort and daily functioning over longer defined time intervals. This research primarily includes Intermediate-term RCTs alongside extensive Observational Studies evaluating daily-life functioning.

---

Key Limitations and Research Gaps

Data for certain groups, such as complex comorbidity-defined groups, remain insufficient. The results apply only to the populations studied, and findings were sometimes mixed across different trials, especially when comparing the medicine to other active drugs. The evidence highlights what is known—and what is still uncertain—including the lack of comprehensive comparative evidence for certain subgroups and the fact that long-term effects are not fully established by high-quality randomized research.

Key Studies & References

1. A single dose of ibuprofen administered orally to treat acute postoperative pain in adults (Cochrane Review)
2. Osteoarthritis in over 16s: diagnosis and management (NICE Guideline NG226)

Common questions about Profinal (FAQ)

Q: Can I stop taking Profinal if my blood pressure is normal?

Do not stop taking the medication without consulting a healthcare professional. Abruptly stopping treatment may lead to a temporary increase in blood pressure, potentially increasing related health risks. Healthcare professionals generally advise continuing treatment as prescribed, even when symptoms are managed, as this medication is intended for long-term management.

Q: How long does it take for Profinal to start working?

Product information suggests that the blood pressure-lowering effect may begin within the first hour of the first dose. However, achieving the full, stable therapeutic benefit may require approximately two weeks of consistent use. Individual responses to medication may vary, and consistent use is necessary to achieve the full therapeutic effect.

Q: Is Profinal safe to take during pregnancy?

Profinal is generally not recommended for use during pregnancy, based on regulatory information. Specifically, use during the second and third trimesters is associated with a risk of injury to the fetus. Patients who may become pregnant are advised to discuss the need for effective birth control options with their healthcare provider. If a patient becomes pregnant while taking this medication, they should contact their prescriber immediately to discuss the treatment plan.

Storage and Disposal of Profinal (Ibuprofen)

Profinal must be stored and disposed of according to official regulatory requirements to ensure product stability and safety.

---

Storage Conditions

Profinal should be kept at controlled room temperature, which is typically 20 C to 25 C (68 F to 77 F). The medicine must be stored in its original container and kept tightly closed to protect it from excessive heat and moisture; regulators advise against storing it in a bathroom.

For safety, Profinal must be stored out of the reach of children and pets.

---

Disposal Instructions

Unused or expired Profinal should be discarded following specific governmental instructions.

• The preferred method is using a drug take-back program where available.
• If a program is unavailable, the medication may be mixed with an unappealing substance (like dirt or used coffee grounds) and sealed in a bag for disposal in the household trash.
• The product must not be flushed down a toilet or poured down a drain unless explicitly instructed by a federal agency.